{"name":"Blue Earth Diagnostics","slug":"blue-earth-diagnostics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2016-01-01","label":"Axumin first approved","drug":"Axumin","drugSlug":"fluciclovine-18f","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Flotufolastat (18F)","genericName":"Flotufolastat (18F)","slug":"flotufolastat-18f","indication":"PET imaging of folate receptor-positive tumors in oncology patients","status":"marketed"},{"name":"piflufolastat (18F)","genericName":"piflufolastat (18F)","slug":"piflufolastat-18f","indication":"PET imaging of PSMA-positive lesions in men with prostate cancer","status":"marketed"},{"name":"rhPSMA-7.3 (18F) Injection","genericName":"rhPSMA-7.3 (18F) Injection","slug":"rhpsma-7-3-18f-injection","indication":"Diagnostic imaging of prostate cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Axumin","genericName":"fluciclovine (18F)","slug":"fluciclovine-18f","indication":"Positron emission tomography","status":"marketed"}]}],"pipeline":[{"name":"Axumin","genericName":"fluciclovine (18F)","slug":"fluciclovine-18f","phase":"marketed","mechanism":"Axumin works by binding to specific sites in the body, emitting positrons that create images during PET scans.","indications":["Positron emission tomography"],"catalyst":""},{"name":"Flotufolastat (18F)","genericName":"Flotufolastat (18F)","slug":"flotufolastat-18f","phase":"marketed","mechanism":"Flotufolastat (18F) is a fluorine-18 labeled folate analog that binds to folate receptors on cancer cells for positron emission tomography (PET) imaging.","indications":["PET imaging of folate receptor-positive tumors in oncology patients"],"catalyst":""},{"name":"piflufolastat (18F)","genericName":"piflufolastat (18F)","slug":"piflufolastat-18f","phase":"marketed","mechanism":"Piflufolastat (18F) is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.","indications":["PET imaging of PSMA-positive lesions in men with prostate cancer","Detection and localization of metastatic prostate cancer"],"catalyst":""},{"name":"rhPSMA-7.3 (18F) Injection","genericName":"rhPSMA-7.3 (18F) Injection","slug":"rhpsma-7-3-18f-injection","phase":"phase_3","mechanism":"rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging.","indications":["Diagnostic imaging of prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNN0lnU3I2dGh6Mlc0MkdaNHBPMXVRSFl5blpLbjhhMThlbktuUlF4YUFJVl9oelZQVGluU19VQ1dhNE8yOUdZaDJMRDVYR0lhMEctNEhuNTNKbkRxVFlfMXB4eXpvVUpfX0JkTW9Hdl81ZzBDWlA1Z0thbGoydXRja0NnQ1dVNENmSzg1ZXpkYmlHR2hpY25vWg?oc=5","date":"2026-04-02","type":"pipeline","source":"openPR.com","summary":"PSMA PET Imaging Market (2026-2033) | Nuclear Medicine Growth, - openPR.com","headline":"PSMA PET Imaging Market (2026-2033) | Nuclear Medicine Growth,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"trial","source":"PR Newswire","summary":"Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in Men with Biochemical Recur","headline":"Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) an","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOVHp0Y2htYjItLUptX0VoSU9MUFlfN0g1LVlXNVBWMTlFSzAxS3Brc2ZWZjBoUUhjMnJ3MTVhSkVvdjJTOE1RVVhQN2xnSDVTaTlxSm0tRWgtXzRORHRHM1FabGV0VGxUQWZOLUNCbTB4SW1QdnV2QkZVVHlUb3VwbUpGS19wSW1FMDlpLWdmVUNvY19FamVOVS13OHk1ajhuY0ZWcjkxMVFMU19jX2d3eGhyZWUxckJaOWNic0JmQkRYMUlQN0dHaDAtc29UT242elUtRDBLVFluRC1XM2FETkI2eVp2UjJMaHltN3EzRlVWUlZQQ3B3OTlram1wUm9RYjZrYl9CNlVpcnFrd2dsUFctQmdVUHo4bFJZVHROQ2xPXzh2ZXdoNWdtVEw?oc=5","date":"2026-02-18","type":"trial","source":"PR Newswire","summary":"Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO Genitourinary Symposium (ASCO GU) - PR Newswire","headline":"Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE4zX0x6eGpkVnZsdnpzMkEzZDJDWWZ6bE82aDJ1VnMyUEFIM09NZVM5STZLa2Vka3JKaWQtVUxhMi1Bdm9vaVh6V3hkcmlBRy1QZllzT0dMYUNwanNuVnFFRzJYRVhUWmlJRVFXNi1xUmRPUWFkVGJzUDBR?oc=5","date":"2026-02-07","type":"trial","source":"MedPage Today","summary":"Similar Prostate Cancer Drugs Show Different Results in Real-World Study - MedPage Today","headline":"Similar Prostate Cancer Drugs Show Different Results in Real-World Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNRm5icmpLZC1qaloxa2JNXzVQa3AwQU5yS0V0Sm9JNTFSdHl6cVlYenI3eTYzNjFWQzNQME5aMlQxU2hfSjBvd0VRZ0t5ZHJ5VFozREtMSnNNWHpVbWZTY3F4Z25vdkxpWTgwT0VYMEIxRmtZT0Z6d1hZYXhodlNJWjhWTGFubUJaU3VXMzJfSHU0M2xaT2JwTWxKT0xGdUNlUVVVdXdR0gGmAUFVX3lxTE1GbmJyaktkLWpqWjFrYk1fNVBrcDBBTnJLRXRKb0k1MVJ0eXpxWVh6cjd5NjM2MVZDM1AwTloyVDFTaF9KMG93RVFnS3lkcnlUWjNES0xKc01YelVtZlNjcXhnbm92TGlZODBPRVgwQjFGa1lPRnp3WFlheGh2U0laOFZMYW5tQlpTdVczMl9IdTQzbFpPYnBNbEpPTEZ1Q2VRVVV1d1E?oc=5","date":"2026-01-08","type":"pipeline","source":"Newswise","summary":"Personalizing Cancer Treatments Significantly Improve Outcome Success | Newswise - Newswise","headline":"Personalizing Cancer Treatments Significantly Improve Outcome Success | Newswise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQQnlRMFI4VGZaaW9fTHlxOFVudVh2UjN3QzlRcEVRWDNqbE1QTGRzV0s2WkNYbWNqZk92QkxPRHp2UWZra2hPN3ZSUklQZ0I0UGRaa0U5MEhnMHppM1NjZ2VRWWhpT3FMQ2JFV0JHVGR6eHl1NjYxOU9US0xLanRhN2hZR3VJM2I4cGJWdDNId3B2UDJEbnVSdzhHdE9vWWprLW1pLW51OHZEWVZZVnVyUThmcmVPakNTMDdJdUVCZTVWWUNsTVhsaEFoOWdTWWVWNi1GSVIwRllVX0VMSkhpVmVpWQ?oc=5","date":"2025-11-18","type":"pipeline","source":"auntminnie.com","summary":"Siemens Healthineers rebrands radiopharmaceutical companies - auntminnie.com","headline":"Siemens Healthineers rebrands radiopharmaceutical companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQVnVxX1ZTdkhjZXJxU2c4d1psNHBEcmk4SlhIUWNDemlZT2cteWtDLUFnUjB1UFl6aTR5bi0wVGV4Nzh0ZHl1RzI2Qk1WRXN5b1JzQVV0S0QzRGNrenhZM243dXZtUXloT2tHYm5nT0pGVlRRQ0MxN2tyYmViR3NQdWVDQ3lILWN6TVBvTWszUFRJSllHZGl0UUM3MTBVTDd0Q2hfSHJYOGtkSU9yY0JLMy1kZUg4ZTJPaWN3b0Qtdw?oc=5","date":"2025-09-24","type":"pipeline","source":"Fierce Biotech","summary":"Lantheus hands GE HealthCare the rights to its blockbuster prostate cancer PET tracer in Japan - Fierce Biotech","headline":"Lantheus hands GE HealthCare the rights to its blockbuster prostate cancer PET tracer in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxONVZna3VDaldKTmVRRldlS3YzVlBneFRkeXBXSy12QWItbkJWYnJkcHFnamFKcU1aWWNPdkdSVUNNYzF1QkR2NEtGemtDMnJ4YXJRaEE3a2k4bWx4aU9NcEdDalZhOGRNcDdMMHdQSllZOWJPWGNrdEVuaGRtNllxQ1JuSWhqSjZrNVZNbXNaX3VxTzdBaWlIT0dTaHYzYndxRjB0YjFRWjBSUGFFZnRUTlZuQ0JPaW1HLTM0bVdpZVBkMnJBR1A5bWY4dXpFckc5endiSw?oc=5","date":"2025-07-23","type":"pipeline","source":"European Medical Journal","summary":"Luteinising Hormone-Releasing Hormone Antagonists in Prostate Cancer: Myths and Facts - European Medical Journal","headline":"Luteinising Hormone-Releasing Hormone Antagonists in Prostate Cancer: Myths and Facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQMGlPaVhEd1hVVlRZOHFCVnJINV9XMVVQV1EyaHgzRVJjSXY2TFJ1eGlSd2FHQXkzblBHQmE0N0xPLVVvRjNkMDNCNlU0bUgtMEZxNGhIV2ZNak5KaVpGRW1FYThnblFyTEF6RHRZMVJkdk5KeUtTSVBrekRYSkVTdlZkQTdNeEw0UTN5aUdjbjZJd1pEZVdLd2RMeFdZangyRXJQWExMWmF0dWljaHBaVjJFN1lfZENWeVhtVzJmMldhZ1hQVVVkUDl0bVhlbmxJTGd1djRtOG5fSFlkSndhSA?oc=5","date":"2025-06-12","type":"pipeline","source":"Radiology Business","summary":"Radiopharma firm Telix launches new prostate cancer imaging agent Gozellix in US - Radiology Business","headline":"Radiopharma firm Telix launches new prostate cancer imaging agent Gozellix in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOQmliNGk1UTZSN3lTeVFBeFVMazFVczczZE1UcllORm45ZnNpOXBlZGRwdlRWSDBLRnlHSVAzSDZIejkyVExkbVZUVURfTmxXZm5ZMlN5cjdOTmFsS184Yk4xbHJ4VzRiSFRoSUZ0NFBhM3JieXprVXVzbFRJSHFrRTVtYjZBQmJtQl9nZUNfLWFYSFNzZHN5NkExdGU3Rm1OdEszUDFLUFQ5RXo3WDNqd01aa1VPNVQ3T25SNzV3Mlp5Ym9fTG1lS3BFdDJTd0s1ZGF0bURKSmxDYTJPa2ctWDVyRmd0X2hJQ2VmVTJ4QWFrdDBZS0JoOEpDV25YWEVpM0NmbUY1ZjF6UkFfNVRxam5ZTlJlUlN6eXRmbm1HQm0wMWtKSldRdl84eHVxallTdVk0ME5vZWR3dkc4MWc?oc=5","date":"2024-11-04","type":"pipeline","source":"Business Wire","summary":"Blue Earth Diagnostics, a Bracco Company, Applauds New CMS Rule to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals - Business Wire","headline":"Blue Earth Diagnostics, a Bracco Company, Applauds New CMS Rule to Support Patient Access Through Improved Payment for S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNeldmZzJJZGtzc3hxZTV4MTI0bGV6Q19HUVlXT0t2QW4zc3c5aE4xaWFmZWk4cGtBdmxnYjdoYWFOeDY2Mk1RLUt6bVhUR2FIZGRTdUE4bk1aSDhqU2dEREI3TlVwQ20tUFRrX2xaSXgyWjRTdzloTFBLUFFqMUk1RE55Q0Zady1pT2lEbW50SnNUODVRb1ZfbVM4QXc0bC16YWllX1V2ekY1S2NxYTFPX3c2bmppYTU1REtn?oc=5","date":"2024-07-09","type":"pipeline","source":"Imaging Technology News","summary":"Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer - Imaging Technology News","headline":"Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNZ3BVbldXcDFnUlVxMjNUUnA4NDVHZXg5OWQ3cmY5SEgybi0xTDhhZE55Y1VVTEo5eEoxVmZEU05HYlRBLVVlWk5sYjhLeU1oVDBpcjBna08wQVJzX28yRlVKa3hLZ2FaVzZmNktUUEtzSENYdVNFMm1FajllcWk1NWI4Sm41TGJ3bjh2aWlEOTViaGJpZ001QktqQTBJNnctVUo4WUFYYlpkb2paem5RMkY3UGlBcHRwN2QyUkN0eVJrcjll?oc=5","date":"2023-10-18","type":"deal","source":"Urology Times","summary":"Collaboration aims to make flotufolastat F 18 available in China for prostate cancer imaging - Urology Times","headline":"Collaboration aims to make flotufolastat F 18 available in China for prostate cancer imaging","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":3,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}